Hoover D L, Smith L E, Turner S J, Gelber R D, Sallan S E
Department of Ophthalmology, Children's Hospital, Boston.
Ophthalmology. 1988 Feb;95(2):151-5. doi: 10.1016/s0161-6420(88)33198-2.
Eighty-two survivors of acute lymphoblastic leukemia (ALL) had prospective eye evaluations to determine the ocular sequelae of the disease and its treatment. All patients had completed or nearly completed a 25- to 31-month protocol which included either 3.4 or 10.2 g of systemic prednisone/m2 per year and cranial irradiation (total 1800-2800 rad). The mean interval from the end of treatment to the eye examination was 32 months. Only one patient had reduced vision attributable to the ALL. Ocular morbidity attributed to the treatment only included posterior subcapsular cataracts (PSCs) which occurred in 52% of patients. Posterior subcapsular cataracts (PSCs) developed in none of the 15 survivors of acute myelogenous leukemia (AML) examined who had received neither long-term systemic prednisone nor irradiation (P = 0.0006). Eyes with PSC had a median visual acuity of 20/20 (range, 20/15-20/50). The authors conclude that the ocular morbidity from antileukemia treatment programs at our institutions is minimal.
82名急性淋巴细胞白血病（ALL）幸存者接受了前瞻性眼部评估，以确定该疾病及其治疗的眼部后遗症。所有患者均已完成或即将完成一个为期25至31个月的方案，该方案包括每年3.4克或10.2克的全身泼尼松/平方米以及头颅照射（总量1800 - 2800拉德）。从治疗结束到眼部检查的平均间隔时间为32个月。只有一名患者因ALL导致视力下降。仅由治疗引起的眼部疾病包括后囊下白内障（PSC），其在52%的患者中出现。在15名既未接受长期全身泼尼松治疗也未接受照射的急性髓细胞白血病（AML）幸存者中，无人出现后囊下白内障（PSC）（P = 0.0006）。患有PSC的眼睛的中位视力为20/20（范围为20/15 - 20/50）。作者得出结论，在我们机构中，抗白血病治疗方案引起的眼部疾病极少。
